# Frequently Asked, Precisely Answered > Metabolic Peptide FAQ — Fit Peptide — Answers to common questions about Metabolic & Weight research peptides, including MOTS-c, tesamorelin, and tirzepatide, with evidence boundaries and citations. **QUESTIONS / EVIDENCE BOUNDARIES** Definitions, mechanisms, uses, and limitations drawn only from the composed research record. ## What does the MOTS-c peptide do? In experimental systems, MOTS-c acts as a mitochondrial-derived signal involved in cellular energy stress. It affects folate and purine metabolism, activates AMPK, can move into the nucleus under stress, and has been linked to skeletal-muscle glucose uptake and homeostasis [1][5][6]. Mouse experiments reported improved treadmill capacity, grip strength, and gait [4]. These are preclinical findings; the supplied corpus contains no human efficacy trial of administered MOTS-c. ## What are the negative side effects of MOTS-c? A reliable human adverse-effect profile cannot be stated from this evidence set because controlled human intervention studies are absent. The cited literature is dominated by cells and animals [1][3][4][5][6][7], while the human study measured circulating MOTS-c observationally [2]. Uncertainty about pharmacokinetics, dose-response, product quality, and longer-term safety is therefore more defensible than a confident list of side effects. ## Is MOTS-c legal to buy? Legality depends on jurisdiction and context, and this site does not provide sourcing guidance. The composed record describes MOTS-c as unapproved for human use and treated as prohibited in elite sport. A product marketed as a research chemical is not thereby validated for human administration. Regulatory status, research-market availability, and permission under sport rules are separate questions. ## How often do you inject MOTS-c? Fit Peptide does not provide a human injection schedule. The corpus states that no validated human pharmacokinetic, bioavailability, dose-response, or efficacy framework exists. Animal protocols cannot be translated into human instructions. Questions about an experimental regimen would exceed what the cited evidence can support and would become medical advice. ## What is tesamorelin? Tesamorelin acetate is a synthetic analogue of growth hormone-releasing hormone. It activates GHRH receptors at the anterior pituitary, increasing pulsatile endogenous growth hormone and downstream IGF-1. It is an approved prescription medicine for reducing excess abdominal fat in adults with HIV-associated lipodystrophy [9]. That specific indication should remain attached to descriptions of its clinical evidence. ## What does tesamorelin do? In trials involving HIV-associated lipodystrophy, tesamorelin reduced visceral adipose tissue, trunk fat, and hepatic fat and increased lean body mass in pooled results [8]. A longer study found the visceral-fat reduction persisted during continued treatment but that fat reaccumulated after discontinuation [12]. These are body-composition outcomes in a defined clinical population, not direct measures of strength or exercise capacity. ## How does tesamorelin work? Tesamorelin activates the pituitary GHRH receptor and amplifies the body’s own pulsatile growth-hormone release. Growth hormone then stimulates hepatic IGF-1 production, and the combined axis promotes lipolysis, particularly in visceral fat. A mechanistic human study measured increases in overnight growth hormone and IGF-1 without significant short-term changes in fasting glucose or insulin-stimulated glucose uptake [11]. ## Will tesamorelin help me lose belly fat? No individual outcome can be predicted here. Randomized trials and a pooled analysis found reduced visceral abdominal fat in adults with HIV-associated lipodystrophy [8][10][12]. That evidence supports a specific approved clinical use, not a general claim for people without the studied condition. Visceral fat also reaccumulated after discontinuation in the long-term program [12]. A licensed clinician must address individual treatment questions. ## What is tirzepatide? Tirzepatide is a synthetic peptide prescription medicine and dual agonist of the GIP and GLP-1 receptors. Those incretin pathways coordinate post-meal insulin, glucagon, gastric emptying, appetite, and food intake. A clinical reference describes its dual mechanism and approved role in type 2 diabetes [14]. Its evidence base also includes major obesity and comparative diabetes trials [13][16][17]. ## How does tirzepatide work? Tirzepatide activates GIPR and GLP-1R. Together, these signals enhance glucose-dependent insulin secretion, suppress glucagon, delay gastric emptying, and reduce appetite and food intake [14]. The mechanism improves glycemic control and lowers energy intake. It is not a demonstrated exercise-mimetic mechanism, and body-weight change should not automatically be interpreted as improved athletic performance. ## What does tirzepatide do in the body? Its principal measured effects in this corpus are lower glycated hemoglobin, lower body weight, and reduced waist circumference [13][16][17]. Gastrointestinal adverse events were common in pivotal trials [16][17]. A pooled safety analysis found a significant increase in the composite of gallbladder or biliary disease but no statistically significant increase in pancreatitis compared with controls [15]. ## What is tirzepatide used for? The composed record describes approved prescription uses in type 2 diabetes, chronic weight management, and obstructive sleep apnea in adults with obesity. The cited subset documents the type 2 diabetes indication and major trial programs for diabetes and obesity [13][14][16][17]. Approved use is distinct from a fitness or performance claim, and this digest does not provide individualized treatment advice. --- Fit Peptide is an independent editorial review of training-adjacent metabolic endpoints, not a clinic, vendor, or prescription.